Adrenal carcinoma

Summary

Adrenal carcinoma (MONDO:0002814) is a cancer and 5 clinical trials. Molecularly, FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion confers sensitivity to Erdafitinib in Adrenal Carcinoma (CIViC Level C). Top therapeutic interventions include lutetium oxodotreotide lu-177 and osilodrostat. A subtype of retroperitoneum carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal carcinoma
Mondo ID	MONDO:0002814
MeSH	D018268
DOID	DOID:3950
GARD	0023252
Anatomy (UBERON)	UBERON:0002369
Is cancer (heuristic)	yes

Also known as: adrenal gland carcinoma · carcinoma of adrenal gland

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › retroperitoneum carcinoma › adrenal carcinoma

Subtypes (2): adrenal medulla carcinoma, adrenal cortex carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06607692	PHASE1/PHASE2	RECRUITING	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
NCT02468193	PHASE2	COMPLETED	Study of Efficacy and Safety of Osilodrostat in Cushing’s Syndrome
NCT06279442	Not specified	RECRUITING	Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort
NCT04666220	Not specified	UNKNOWN	VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma
NCT04890444	Not specified	UNKNOWN	China Adrenal Disease Registry

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LUTETIUM OXODOTREOTIDE LU-177	4	1
OSILODROSTAT	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion	Erdafitinib	Sensitivity/Response	CIViC C	EID4861